Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.
Ribocure Pharmaceuticals AB, a subsidiary of Suzhou Ribo Life Science Co. Ltd., and Madrigal Pharmaceuticals Inc. have achieved the first drug candidate nomination within their siRNA partnership.
Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.
Shanghai Zheye Biotechnology LLC has discovered new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.
Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have synthesized new GTPase KRAS G12C mutant inhibitors potentially useful for the treatment of cancer, autoimmune disorders and inflammatory disorders.
Monte Rosa Therapeutics AG has reported new molecular glue degraders comprising an E3 ubiquitin-protein ligase-binding moiety acting as E3 G1/S-specific cyclin-E1 (CCNE1)/cereblon interaction inducers and CCNE1 degradation inducers potentially useful for the treatment of cancer.
Bayer AG has patented new potassium channel Kir3.4 (GIRK4; KCNJ5) and/or Kir3.1/3.4 (GIRK1/4; KCNJ3/5) blockers potentially useful for the treatment of heart failure, arrhythmia, primary hyperaldosteronism and hypertension.
A team at the University of California, Los Angeles (UCLA) found that injured kidneys produce ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1), a protein that hydrolyzes extracellular ATP into AMP and pyrophosphate, and that impedes tissue repair.
RSS
